ARVN · Arvinas, Inc. · Webcasts, Transcripts & Audio
$7.43
-0.31 (-3.94%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$486.47M
Shares
65.39M
Volume · Oct 1
807.32K
Avg daily vol (3M)
784.84K
Arvinas, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Arvinas, Inc. (ARVN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲196%
$102.40M
−$49.20M
'24 Q3
24-10-30
·
$59.20M
−$45.10M
'24 Q4
25-02-11
▲646.2%
$188.80M
$82.90M
'25 Q1
25-05-01
▼70.7%
$22.40M
−$61.20M
'25 Q2
25-08-06
▼59.1%
$41.90M
−$35.10M
'25 Q3
25-11-05
▼84%
$9.50M
−$67.40M
'25 Q4
26-02-24
▼91.7%
$15.60M
−$57.60M
'26 Q1
26-05-12
LATEST
▲1014.7%
$249.70M
$169.40M
'26 Q2
26-08-04
Conference
Investor event
2026-09-17
Arvinas, Inc. (ARVN) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-08
Arvinas, Inc. (ARVN) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Positive tone
ARV-027 / SBMA program
ARV102 / LRRK2 in PSP and PD
ARV393 / BCL-6 degrader
Revenue
$249.70M
▲ 1014.7% YoY Diluted EPS
$2.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Arvinas, Inc. (ARVN) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-12
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Confident tone
ARV-102 in PSP / Parkinson's
Pipeline and PROTAC platform
KRAS G12D degrader (ARV-806)
Revenue
$15.60M
▼ 91.7% YoY Diluted EPS
$-0.90
▼ 178.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Confident tone
ARV-102 LRRK2 degrader in Parkinson's and PSP
Regulatory interactions and registrational path
ARV-806 KRAS G12D PROTAC
Revenue
$9.50M*
▼ 84% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript
Confident tone
ARV-102 LRRK2 degrader
ARV-393 BCL6 degrader
ARV-806 KRAS G12D degrader
Revenue
$41.90M
▼ 59.1% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
Positive tone
Vepdeg/Pfizer collaboration uncertainty
PROTAC pipeline progression
LRRK2 degrader ARV-102 in neuroscience
Revenue
$22.40M
▼ 70.7% YoY Diluted EPS
$-0.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript
Positive tone
VEPDEG VERITAC-2 pivotal data and regulatory filing
Pfizer joint development plan changes
Second-line ESR1 mutant market opportunity
Revenue
$188.80M
▲ 646.2% YoY Diluted EPS
$1.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript
Confident tone
Phase 3 combination trials in 1L and 2L
Vepdegestrant (vepdeg) ER degrader program
VERITAC-2 Phase 3 trial
Revenue
$59.20M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript
Positive tone
Vepdeg combination strategy (TACTILE/VERITAC-3)
Pfizer partnership and commercialization transition
ARV-102 neuroscience / LRRK2
Revenue
$102.40M
▲ 196% YoY Diluted EPS
$-0.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–11 of 11 webcasts